$0.76
+0.00 (+0.65%)
Open$0.75
Previous Close$0.75
Day High$0.77
Day Low$0.75
52W High$1.80
52W Low$0.48
Volume—
Avg Volume413.6K
Market Cap16.35M
P/E Ratio—
EPS$-1.31
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,567.5% upside
Current
$0.76
$0.76
Target
$27.69
$27.69
$21.92
$27.69 avg
$40.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.48M | 1.49M | 3.54M |
| Net Income | -27,969,022 | -25,331,709 | -86,327 |
| Profit Margin | -1,893.6% | -1,798.9% | -2.4% |
| EBITDA | -26,457,651 | -25,294,121 | -134,724 |
| Free Cash Flow | — | — | -61,141 |
| Rev Growth | -0.6% | -0.6% | +8.8% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |